Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared on LinkedIn:
“What if CAR-NK cells could be engineered not just to survive the tumor microenvironment – but to actively remodel it?
Solid tumors remain a formidable challenge for cellular immunotherapy because the tumor microenvironment can suppress immune-cell persistence, metabolism, and effector function.
IL-12 is a powerful activator of antitumor immunity, but systemic IL-12 therapy has been limited by toxicity.
This study takes a different approach: build IL-12 signaling directly into CAR-NK cells while restricting where the cytokine acts.
The investigators found that CAR activation and IL-12 signaling synergized to sustain mTORC1 activity through convergent Ras-ERK and PI3K pathways, promoting:
- Metabolic fitness
- Autonomous NK-cell expansion
- Sustained effector function
- But the effect extended beyond the engineered cells.
- IL-12 activated bystander NK cells, T cells, and macrophages, helping remodel the surrounding tumor microenvironment.
To address systemic toxicity, IL-12 was tethered to a collagen-binding A3 domain, anchoring its activity to the extracellular matrix and limiting systemic exposure.
In ovarian and pancreatic cancer models, these matrix-anchored IL-12 CAR-NK cells expanded without exogenous cytokine support and produced durable tumor control.
The bigger idea is fascinating:
CAR-T/NK engineering may be moving from ‘give the cell a better weapon’ toward ‘reprogram the entire immune ecosystem around the cell.’
Here, the CAR provides antigen-specific activation, IL-12 reinforces immune signaling, and mTORC1 serves as a metabolic integration point that helps sustain the response.
The major question now is whether this combination of cell-intrinsic fitness + localized cytokine signaling + microenvironment remodeling can translate from models into patients with solid tumors – without recreating the systemic toxicity that has historically limited IL-12 therapy.”
Title: Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks
Authors: Mubin Tarannum, Khanhlinh Dinh, Mila Stanojevic, Maily Nguyen, Marco Campisi, Andreia Maia, Fuguo Liu, Shaobo Yang, Grace C. Birch, Eden Bobilev, Ian Gillanders, Michal Sheffer, Shikha Gupta, Junning Wang, Suthakar Ganapathy, Daniel E. Michaud, Guillermo Nicolas. Dalton, Seema Chugh, Quang-De Nguyen, Cloud P. Paweletz, Prafulla C. Gokhale, Yang Gao, Jose Cancelas, Jennifer L. Guerriero, Toni K. Choueiri, David A. Barbie, Andrew J. Aguirre, Rebecca L. Porter, Ursula A. Matulonis, John Koreth, Catherine J. Wu, Robert J. Soiffer, Jerome Ritz, Jianzhu Chen, Rizwan Romee
Read the full article here.
Read more articles featuring Yan Leyfman on OncoDaily.